Sickle Cell Disease Association of Tarrant County

Emmaus Life Sciences announced that expects to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) next month for its lead investigational treatment for sickle cell disease.

Emmaus’ lead candidate is an oral pharmaceutical grade L-glutamine treatment that demonstrated positive clinical results in a completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia. The therapy has Orphan Drug designation in the U.S. and Europe, and also received Fast Track designation from the FDA.

The NDA submission will coincide with National Sickle Cell Disease Awareness Month, dedicated to raising public awareness of this complex and serious disease… Click here for complete story.

Leave a Reply

Your email address will not be published. Required fields are marked *